July 28 (Reuters) – GSK launched a £1.9 billion ($2.52 billion) cost-savings drive on Tuesday to help fund the British drugmaker's expanded late-stage study roster, aiming to deliver on CEO Luke Miels
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Gucci's Demna blends aristocracy and pop culture at Milan Fashion Week
MILAN, Sept 25 (Reuters) - Gucci designer Demna on Friday unveiled what he described as…
EU vote on Tesla's supervised self-driving system pushed back
By Marie Mannes STOCKHOLM, Sept 25 (Reuters) - An expected European Union vote on allowing…
REUTERS NEXT- FTC chair pushes back on treating AI agents as independent actors
Sept 25 (Reuters) - U.S. Federal Trade Commission Chairman Andrew Ferguson said on Friday he…
